NDAINTRAVENOUSINJECTABLEPriority Review
Approved
Jan 2011
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sodium Fluoride F-18 is a positron-emitting radiopharmaceutical used as a diagnostic imaging agent in PET scans to detect bone metastases and assess skeletal integrity. It accumulates in areas of increased osteogenic activity, enabling clinicians to identify bone lesions and monitor disease progression in oncology and orthopedic patients.
LOE Approaching
Product is approaching loss of exclusivity with limited linked job opportunities, indicating a contracting commercial footprint and reduced team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Sodium Fluoride F-18 offers exposure to niche diagnostic imaging and radiopharmaceutical expertise, but zero linked job openings signal a mature, stable-sized team with limited growth prospects. This role suits professionals seeking specialized technical depth over career expansion.
Medical Science LiaisonRegulatory Affairs Specialist
Worked on SODIUM FLUORIDE F 18 at Imagin Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.